News
The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
Health and Me on MSN17h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
Investor's Business Daily on MSN23h
Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.
Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback